Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA.
Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Nat Genet. 2018 May;50(5):708-717. doi: 10.1038/s41588-018-0105-0. Epub 2018 Apr 23.
To understand how genomic heterogeneity of glioblastoma (GBM) contributes to poor therapy response, we performed DNA and RNA sequencing on GBM samples and the neurospheres and orthotopic xenograft models derived from them. We used the resulting dataset to show that somatic driver alterations including single-nucleotide variants, focal DNA alterations and oncogene amplification on extrachromosomal DNA (ecDNA) elements were in majority propagated from tumor to model systems. In several instances, ecDNAs and chromosomal alterations demonstrated divergent inheritance patterns and clonal selection dynamics during cell culture and xenografting. We infer that ecDNA was unevenly inherited by offspring cells, a characteristic that affects the oncogenic potential of cells with more or fewer ecDNAs. Longitudinal patient tumor profiling found that oncogenic ecDNAs are frequently retained throughout the course of disease. Our analysis shows that extrachromosomal elements allow rapid increase of genomic heterogeneity during GBM evolution, independently of chromosomal DNA alterations.
为了了解胶质母细胞瘤(GBM)的基因组异质性如何导致治疗反应不佳,我们对 GBM 样本以及从中衍生的神经球和原位异种移植模型进行了 DNA 和 RNA 测序。我们利用所得数据集表明,包括单核苷酸变异、焦点 DNA 改变和染色体外 DNA(ecDNA)元件上的致癌基因扩增在内的体细胞驱动改变,在大多数情况下从肿瘤传播到模型系统。在某些情况下,ecDNA 和染色体改变在细胞培养和异种移植过程中表现出不同的遗传模式和克隆选择动态。我们推断 ecDNA 被后代细胞不均匀地遗传,这一特征影响了具有更多或更少 ecDNA 的细胞的致癌潜力。对患者肿瘤的纵向分析发现,致癌 ecDNA 在疾病的整个过程中经常保留。我们的分析表明,在 GBM 进化过程中,ecDNA 允许基因组异质性的快速增加,这与染色体 DNA 改变无关。